following the announcement of “unprecedented” 12-month efficacy data from a Phase 2 study of the biopharma’s major depressive ...

The team noted, “These findings suggest that bright light therapy was an effective adjunctive ... Psychiatric Association has ...

Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment ...

Acupuncture. Ketamine infusions. "Electroshock" or electroconvulsive therapy. The existing treatment options for those ...

The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...

TORONTO--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough ...

Bright light therapy, a standard treatment for seasonal depression, may also help people who experience depression year-round ...

Patients with non-seasonal depression who were treated with bright light therapy reported a 40% remission rate, according to a recent study.

(RTTNews) - Silo Pharma, Inc. (SILO), Monday announced positive results from a pre-clinical study of SPC-15 showing potential for the treatment of major depressive disorder ... The combination therapy ...

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...

Bright light therapy was associated with improved treatment response and remission rates among patients with nonseasonal depression.

The Horizon 3.0 TMS Therapy System is a computerized, noninvasive medical device that directs electrical currents at different regions of the cerebral cortex.